At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 19, 2026 at 14:00 ET
Revolution Medicines announced updated Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung cancer, showing a 52% confirmed objective response rate and 11.1-month median progression-free survival, supporting its potential as a first-in-class targeted therapy for a high-unmet-need population.
- Zoldonrasib showed a 52% confirmed objective response rate (ORR) in 27 evaluable KRAS G12D NSCLC patients previously treated with immunotherapy and chemotherapy.
- Median progression-free survival (PFS) was 11.1 months, with a 12-month PFS rate of 48%.
- The safety profile was manageable, with Grade 3 treatment-related adverse events in 13% of patients and no Grade 4 or 5 events.
- Data were presented at AACR 2026 and represent a key milestone in validating zoldonrasib’s clinical potential.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access